| Dr Carolyn Mccomas Greely, DNP | |
|
500 Upper Chesapeake Dr, Bel Air, MD 21014-4324 | |
| (443) 643-2000 | |
| Not Available |
| Full Name | Dr Carolyn Mccomas Greely |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 500 Upper Chesapeake Dr, Bel Air, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104442326 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | R206224 (Maryland) | Primary |
| Entity Name | Upper Chesapeake Emergency Medicine Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285854026 PECOS PAC ID: 2860587342 Enrollment ID: O20070927001103 |
News Archive
It is difficult to imagine a depressed third-grader. It is even more difficult to imagine a depressed preschooler. Although childhood depression is a well-recognized and treated disorder, only recently have research studies begun looking at depression in children younger than six years old.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
University of Illinois at Chicago researchers are comparing two drugs used to treat pediatric bipolar disorder patients to evaluate how the drugs affect brain function in children with the disorder.
This year's World Health Day focuses on the growing threat of potentially deadly infections developing resistance to antimicrobial drugs - especially to antibiotics. On this occasion, the European Commission is presenting the promising results of two EU-funded international research projects which provide new hopes to help and treat people.
Amgen today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab's superiority over Zometa in delaying or preventing skeletal related events (SREs).
› Verified 2 days ago
| Entity Name | Upper Chesapeake Cardiology, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851544159 PECOS PAC ID: 4183788847 Enrollment ID: O20090126000459 |
News Archive
It is difficult to imagine a depressed third-grader. It is even more difficult to imagine a depressed preschooler. Although childhood depression is a well-recognized and treated disorder, only recently have research studies begun looking at depression in children younger than six years old.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
University of Illinois at Chicago researchers are comparing two drugs used to treat pediatric bipolar disorder patients to evaluate how the drugs affect brain function in children with the disorder.
This year's World Health Day focuses on the growing threat of potentially deadly infections developing resistance to antimicrobial drugs - especially to antibiotics. On this occasion, the European Commission is presenting the promising results of two EU-funded international research projects which provide new hopes to help and treat people.
Amgen today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab's superiority over Zometa in delaying or preventing skeletal related events (SREs).
› Verified 2 days ago
| Entity Name | Clinical Associates P A |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871973628 PECOS PAC ID: 1254631005 Enrollment ID: O20151130000953 |
News Archive
It is difficult to imagine a depressed third-grader. It is even more difficult to imagine a depressed preschooler. Although childhood depression is a well-recognized and treated disorder, only recently have research studies begun looking at depression in children younger than six years old.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
University of Illinois at Chicago researchers are comparing two drugs used to treat pediatric bipolar disorder patients to evaluate how the drugs affect brain function in children with the disorder.
This year's World Health Day focuses on the growing threat of potentially deadly infections developing resistance to antimicrobial drugs - especially to antibiotics. On this occasion, the European Commission is presenting the promising results of two EU-funded international research projects which provide new hopes to help and treat people.
Amgen today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab's superiority over Zometa in delaying or preventing skeletal related events (SREs).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Carolyn Mccomas Greely, DNP 11612 Cedar Ln, Kingsville, MD 21087-1648 Ph: (443) 545-4754 | Dr Carolyn Mccomas Greely, DNP 500 Upper Chesapeake Dr, Bel Air, MD 21014-4324 Ph: (443) 643-2000 |
News Archive
It is difficult to imagine a depressed third-grader. It is even more difficult to imagine a depressed preschooler. Although childhood depression is a well-recognized and treated disorder, only recently have research studies begun looking at depression in children younger than six years old.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
University of Illinois at Chicago researchers are comparing two drugs used to treat pediatric bipolar disorder patients to evaluate how the drugs affect brain function in children with the disorder.
This year's World Health Day focuses on the growing threat of potentially deadly infections developing resistance to antimicrobial drugs - especially to antibiotics. On this occasion, the European Commission is presenting the promising results of two EU-funded international research projects which provide new hopes to help and treat people.
Amgen today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa® (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumab's superiority over Zometa in delaying or preventing skeletal related events (SREs).
› Verified 2 days ago
Alison Ann Mclaughlin, CRNP-PMH Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4 North Ave # 420, Bel Air, MD 21014 Phone: 443-752-9610 | |
Arielle Deasel, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 615 W Macphail Rd Ste 106, Bel Air, MD 21014 Phone: 443-504-4359 | |
Joan Marie Hare, MSN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 580 Marketplace Dr, Bel Air, MD 21014 Phone: 410-375-4136 | |
Tracy Lynn Crose-hamm, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 730 Baltimore Pike, Bel Air, MD 21014 Phone: 410-887-8077 | |
Sarah Rangelov, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 120 S Hays St, Bel Air, MD 21014 Phone: 410-838-1500 | |
Tiffany D Lopez, MSN, CRNP, WHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 520 Upper Chesapeake Dr Ste 301, Bel Air, MD 21014 Phone: 443-643-4300 | |
Mrs. Yolanda Caprice Chandler, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 5 Bel Air South Pkwy Ste 1535, Bel Air, MD 21015 Phone: 410-569-2441 Fax: 410-569-2331 |